ProBio
ProBio, a U.S. subsidiary of GenScript Biotech Corp., has end-to-end capabilities for biologics discovery & development. With facilities in the U.S., Netherlands, South Korea, and China, ProBIo has enabled its global partners to obtain more than 90 IND approvals since 2017.
More recently, ProBio has committed to internally develop antibody-based therapeutics available for out-licensing, highlighted by the T cell engager candidates derived from our unique CD3 VHH platform. ProBio has extended its biologics innovation capabilities into designing the next generation of T cell engagers, including those with masking and co-stimulatory domains for enhanced safety and efficacy for oncology and autoimmune indications.
Towards the mission of “Innovation through Collaboration,” ProBio is committed to helping partners accelerate the development & commercialization of biologics in order to shape a healthier future
